Remdesivir may benefit adults early in COVID-19 course – Consumer Health News

FRIDAY, Jan. 28, 2022 (HealthDay News) — Hospitalized COVID-19 patients not receiving oxygen or low-flow oxygen were more likely to achieve clinical improvement within 28 days if treated with remdesivir , according to a study published online in December 15 in Clinical infectious diseases.

Brian T. Garibaldi, MD, of Johns Hopkins University in Baltimore, and colleagues retrospectively assessed the effectiveness of remdesivir for the treatment of COVID-19. The analysis included 18,328 hospitalized patients with confirmed COVID-19 (February 23, 2020 through February 11, 2021) who received at least one dose of remdesivir and matched COVID-19 patients not receiving remdesivir.

Researchers found that 74% of remdesivir-treated patients showed clinical improvement within 28 days (median time of seven days) compared to 68.3% of control patients (median time of nine days). People treated with remdesivir were significantly more likely to achieve clinical improvement at 28 days (adjusted relative risk [aHR], 1.19; 95% confidence interval [CI], 1.16 to 1.22). Clinical improvement was more likely to be achieved at 28 days for remdesivir-treated patients without oxygen (aHR, 1.30; 95% CI, 1.22 to 1.38) or low-flow oxygen (aHR, 1.23; 95% CI, 1.19 to 1.27) . For overall mortality, no significant impact was observed (aHR, 1.02; 95% CI, 0.97 to 1.08). However, remdesivir recipients on low-flow oxygen were significantly less likely to die than controls (aHR, 0.85 [95 percent CI, 0.77 to 0.92]; mortality at 28 days, 8.4% for remdesivir patients versus 12.5% ​​for controls).

“We have observed that it is best to use remdesivir as early as possible, before the patient progresses to high oxygen levels or intubation and mechanical ventilation,” Garibaldi said in a statement. “Most patients who need this kind of advanced respiratory support are probably past the point where antiviral therapies like remdesivir would be effective.”

Several authors disclosed financial ties to pharmaceutical companies, including Gilead, the maker of remdesivir.

Abstract/Full text (subscription or payment may be required)

Comments are closed.